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ABSTRACT
Questions
What is the role of single-agent temozolomide in the
treatment of patients with metastatic melanoma?
In comparison with single-agent temozolomide,
does the addition of interferon-a to temozolomide
improve disease-free survival, overall survival, or re-
sponse rates?
In comparison with single-agent temozolomide,
does the addition of thalidomide to temozolomide im-
prove disease-free survival, overall survival, or re-
sponse rates?
Perspectives
Because of its oral route of administration and its
ability to cross the blood–brain barrier, temozolo-
mide is a potentially attractive chemotherapy agent
for adult patients with unresectable metastatic ma-
lignant melanoma. To provide treatment recommen-
dations for this new agent, the Melanoma Disease
Site Group (DSG) of Cancer Care Ontario’s Program
in Evidence-Based Care (PEBC) decided to review the
available literature on single-agent temozolomide
and on temozolomide in combination with inter-
feron-a or thalidomide.
Outcomes
Outcomes of interest included response rates, disease-
free survival, overall survival, quality of life, and
adverse effects.
Methodology
Evidence was selected and reviewed by two mem-
bers of the Melanoma DSG and by methodologists.
The present practice guideline report was reviewed
and approved by the Melanoma DSG, which comprises
medical and radiation oncologists, surgeons, and der-
matologists. External review was obtained through a
mailed survey of Ontario practitioners, the results of
which were reflected in revisions to the practice
guideline. Final approval of the guideline report was
obtained from the Report Approval Panel of the PBEC.
Practice Guideline
These recommendations apply to adult patients with
unresectable metastatic malignant melanoma.
It is reasonable to use temozolomide at a dose of
200 mg/m2 orally for 5 days every 4 weeks as initial
systemic treatment for patients with unresectable
metastatic malignant melanoma.
The addition of moderate-dose interferon-a 2b
has produced a significantly higher response rate than
has single-agent temozolomide in a large random-
ized phase III study. However, overall survival was
not altered, and grades 3 and 4 hematologic toxici-
ties were higher with the combined treatment. At the
present time, the addition of interferon-a to temo-
zolomide is not recommended.
One randomized phase II study and six other
phase II studies showed encouraging response rates
when thalidomide was combined with temozolomide.
However, the doses and schedules of temozolomide
in those studies differed from the conventionally pre-
scribed doses and schedules. It is not clear whether
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the improved response rates were attributable to the
small number of patients in the studies, the different
temozolomide doses and schedules, or the addition
of thalidomide. Further phase III studies are required
to confirm whether a benefit is associated with the
combination of temozolomide and thalidomide.
Therefore, at this time, it is not recommended that
thalidomide be combined with temozolomide.
Qualifying Statements
Dacarbazine is the only chemotherapy drug currently
approved for the treatment of metastatic malignant
melanoma. In large randomized trials, response rates
with dacarbazine ranged from 6% to 15%. Almost
all responses were partial, with a median response
duration of only 7–8 months. Given these disappoint-
ing overall results, the consensus among most physi-
cians who are treating patients with metastatic
malignant melanoma is that recommending more
convenient treatment or experimental treatment to
these patients is appropriate.
Because of oral dosing, temozolomide is a rea-
sonable choice, particularly for patients who would
have difficulty traveling to cancer centres for intra-
venous chemotherapy.
Temozolomide has demonstrated efficacy equal
to that of dacarbazine in a randomized phase III trial.
However, unlike dacarbazine, temozolomide is a con-
venient oral treatment that penetrates the blood–brain
barrier and that has shown activity against brain me-
tastases. Although surgery is the preferred treatment
modality for patients with solitary brain metastases
from melanoma, temozolomide is the preferred che-
motherapy for patients with brain metastases who re-
quire systemic treatment.
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1. QUESTIONS
What is the role of single-agent temozolomide in the
treatment of patients with metastatic melanoma?
In comparison with single-agent temozolomide, does
the addition of interferon-a to temozolomide improve
disease-free survival, overall survival, or response rates?
In comparison with single-agent temozolomide, does
the addition of thalidomide to temozolomide improve
disease-free survival, overall survival, or response rates?
Outcomes of interest included response rates, dis-
ease-free survival, overall survival, quality of life, and
adverse effects.
2. CHOICE OF TOPIC AND RATIONALE
It has been estimated that, during 2005, 4400 new
cases of melanoma will have been diagnosed in
Canada and that, of 880 estimated deaths from the
disease, 420 will have occurred in Ontario 1. Primary
surgical treatment cures most patients diagnosed with
early-stage malignant melanoma. However, people
with deeply invasive melanoma have a high prob-
ability of developing distant metastases. Adjuvant
therapy has been found to be partially effective, but
the currently available systemic treatments have
yielded disappointing results.
Recently, temozolomide has emerged as a prom-
ising novel chemotherapy agent in malignant mela-
noma. Temozolomide acts through the same
mechanism as dacarbazine; however, unlike dacar-
bazine, temozolomide has excellent oral bioavail-
ability and possesses the ability to cross the
blood–brain barrier. These added benefits suggest that
temozolomide may play a role in treating patients with
metastases to the brain, a frequent metastatic site in
melanoma.
To provide treatment recommendations for this
new agent, the Melanoma Disease Site Group (DSG)
decided to review the available literature on single-
agent temozolomide and on temozolomide in com-
bination with interferon-a or thalidomide.
3. METHODS
3.1 Guideline Development
This practice guideline report was developed by Can-
cer Care Ontario’s Program in Evidence-Based Care
(PEBC) using the methods of the practice guidelines
development cycle 2. Evidence was selected and re-
viewed by two members of the Melanoma DSG and
by methodologists. Members of the Melanoma DSG
disclosed potential conflict of interest information.
The practice guideline is a convenient and up-to-
date source of the best available evidence on single-
agent temozolomide or temozolomide in combination
with interferon-a or thalidomide in the treatment of
metastatic melanoma. The present report was devel-
oped through systematic reviews, evidence synthe-
sis, and input from practitioners in Ontario. It is a
companion piece to a systematic review which is
currently under consideration for publication else-
where. Both documents are intended to promote evi-
dence-based practice in Ontario, Canada. The PEBC is
editorially independent of Cancer Care Ontario and
the Ontario Ministry of Health and Long-Term Care.
3.2 Literature Search Strategy
The MEDLINE [1966 to September (week 3) 2005],
EMBASE (1980 to week 40, 2005), and the Cochrane
Library (Issue 3, 2005) were systematically searched
using a combination of the following terms: “mela-
noma” [Medical Subject Heading, Excerpta Medica
Tree (EMTREE) term, and text word], “temozolomide”
(EMTREE term and text word), “temodal” (text word),
and “temodar” (text word). Those terms were thenPRACTICE GUIDELINE SERIES
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combined with the search terms for the following
publication types and study designs: practice guide-
lines, systematic reviews, meta-analyses, randomized
controlled trials, and controlled trials.
In addition, the proceedings of the 1997–2005
annual meetings of the American Society of Clinical
Oncology were searched for reports of newly com-
pleted trials. Relevant articles and abstracts were se-
lected and reviewed by two reviewers, and the
reference lists from those sources were searched for
additional trials, as were the reference lists from rel-
evant review articles.
4. RESULTS
4.1 Literature Search
The literature search identified two randomized
phase III trials and three randomized phase II trials of
single-agent temozolomide compared with either
single-agent intravenous dacarbazine or combinations
of temozolomide with cisplatin, interferon-a 2b (IFN),
or thalidomide. Another nine phase II and phase I tri-
als investigating single-agent temozolomide, six tri-
als investigating temozolomide plus interferon-a, and
six trials investigating temozolomide plus thalidomide
were reviewed. Sixteen of the trials were published
as full reports; ten were available in abstract form
only.
4.2 Outcomes
4.2.1 Randomized Phase III Trials
Evidence from the two randomized trials 3,4 shows
that it is reasonable to use temozolomide as initial
treatment for patients with unresectable metastatic
malignant melanoma. The first trial 3 compared
single-agent temozolomide with single-agent intra-
venous dacarbazine in 305 patients. The second trial 4
compared single-agent temozolomide with tem-
ozolomide combined with IFN in 294 patients.
Results from the first trial, by Middleton et al.,
demonstrated that progression-free survival was sig-
nificantly prolonged in patients treated with
temozolomide, with a reported hazard ratio (HR) of
1.37 [95% confidence interval (CI): 1.07 to 1.75;
p = 0.012]. Median survival for patients treated with
temozolomide was 7.7 months versus 6.4 months for
those treated with dacarbazine. However, the differ-
ence between the two treatment groups was not sta-
tistically significant. Of the patients in the
temozolomide arm, 21 (14%) showed an objective
response to treatment; of patients in the dacarbazine
arm, 18 (12%) showed an objective response.
Grades 3 and 4 hematologic toxicities were similar
in the two treatment arms.
Kaufmann et al. 4 reported a significantly higher
response rate for temozolomide combined with IFN
as compared with single-agent temozolomide (24%
vs. 13%; p < 0.036). In the combination arm, 11 pa-
tients (8%) achieved a complete response, and 22 pa-
tients (16%) showed a partial response, as compared
with 3 patients (2%) and 15 patients (11%) respec-
tively in the temozolomide group. The median over-
all survival was reported to be 8.4 months in the
temozolomide group (95% CI: 7.07 to 9.72) and
9.7 months in the temozolomide plus IFN group (95%
CI: 8.26 to 11.18); no statistical significance was
detected.
4.2.2 Randomized Phase II Trials
The systematic review identified three randomized
phase II trials 5–7. In the first trial 5, 127 patients were
randomized to receive temozolomide alone or in com-
bination with cisplatin. The second trial 6 random-
ized 181 patients to receive temozolomide alone or
temozolomide combined with either IFN or thalido-
mide. The third trial 7 randomized 47 patients to a
treatment combination of temozolomide and IFN, the
latter being administered in two different dosages.
None of trials detected statistically significant differ-
ences in median overall survival, time to disease pro-
gression, or objective response.
Interestingly, the trial 5 by Bafaloukos and col-
leagues detected some evidence of antitumour activ-
ity in the central nervous system, including 3 partial
responses in brain metastases (1 in the temozolomide
arm and 2 in the combination arm). Only 16% of
patients receiving temozolomide alone and 18% of
patients receiving temozolomide with cisplatin de-
veloped central nervous system metastases (median
follow-up of 39.9 months and 37 months, respec-
tively), further suggesting that treatment with
temozolomide may reduce the occurrence of brain
metastases.
4.2.3 Single-Arm Phase II and I Trials
Phase II and I trials of single-agent temozolomide have
demonstrated response rates that range from 0% to
29%, with complete responses observed in 0%–17%
of patients. Phase II and I trials investigating tem-
ozolomide in combination with either IFN or thalido-
mide have reported response rates ranging from 13%
to 23% and from 8% to 42% respectively. Although
these response rates are encouraging, further evidence
from randomized trials is required.
5. DSG CONSENSUS PROCESS
The practice guideline recommendations were drafted
by one member of the Melanoma DSG and circulated
to the entire DSG in February 2004 for review and
consensus. The members of the Melanoma DSG unani-
mously agreed with the draft recommendations. Be-
fore submitting the recommendations to the Report
Approval Panel, the DSG members discussed adding
a recommendation regarding the use of temozolomide
for patients with brain metastases who require sys-QUIRT et al.
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temic treatment. However, after some debate, the
members decided to address that issue in a qualify-
ing statement.
6. PRACTITIONER FEEDBACK
6.1 Methods
Following discussion and consensus, the Melanoma
DSG circulated the clinical practice guideline and sys-
tematic review to clinicians in Ontario for review.
Feedback was obtained through a mailed survey of
13 practitioners in Ontario (all medical oncologists).
The survey consisted of items evaluating the meth-
ods, results, and interpretive summary used to inform
the draft recommendations and asking whether the
draft recommendations should be approved as a prac-
tice guideline. Written comments were invited. The
survey was mailed on April 23, 2004. Follow-up re-
minders were sent at 2 weeks (post card) and 4 weeks
(complete package mailed again). The Melanoma DSG
reviewed the results of the survey.
6.2 Results
Of the 13 practitioners surveyed, 8 (62%) responded.
Responses include returned completed surveys and
telephone, fax, and e-mail responses. Of the practi-
tioners who responded, 6 indicated that the report
was relevant to their clinical practice, and they com-
pleted the survey. All practitioners indicated that they
agreed with the draft recommendations as stated, and
most agreed that the document should be approved
as a practice guideline. Table I summarizes key re-
sults of the practitioner feedback survey.
6.3 Summary of Written Comments
Four respondents (67%) provided written comments.
The main points contained in the written comments
were these:
• One practitioner commented that experience with
the 6-week 50–75 mg/m2 daily regimen is ad-
equate to include it as a reasonable treatment
option.
• Another practitioner commented that temozol-
omide is a reasonable choice of therapy only in-
sofar as dacarbazine is reasonable. Dacarbazine
should be the “default” option, and temozolomide
should be used only under unusual circum-
stances—for example, when patients live in
remote areas or lack access to intravenous treat-
ment—and even then, monitoring the patient’s
counts is important.
• Finally, a practitioner commented that the roles
of interferon and thalidomide should be revisited
in a timely manner. Also, a need exists to address
the funding of temozolomide in a timely manner
so that it is accessible to patients.
6.4 Modifications/Actions
The Melanoma DSG discussed the comments result-
ing from practitioner feedback survey and responded
as follows:
• Although experience with the 6-week 50–75 mg/m2
daily regimen is growing, the evidence is cur-
rently insufficient to endorse or adopt this treat-
ment regimen in metastatic melanoma.
TABLE I Practitioner responses to eight items on the practitioner feedback survey
Item Respondents who [n (%)]
Strongly agree or agree Neither agree nor disagree Strongly disagree or disagree
The rationale for developing a clinical practice 6 (100) 0 0
guideline, as stated in the “Choice of Topic”
section of the report, is clear.
There is a need for a clinical practice guideline on 6 (100) 0 0
this topic.
The literature search is relevant and complete. 6 (100) 0 0
The results of the trials described in the report are 6 (100) 0 0
interpreted according to my understanding of
the data.
The draft recommendations in this report are clear. 6 (100) 0 0
I agree with the draft recommendations as stated. 6 (100) 0 0
This report should be approved as a practice guideline. 5 (83) 1 (17) 0
Very likely or likely Unsure Not at all likely or unlikely
If this report were to become a practice guideline, 4 (67) 0 2 (33)
how likely would you be to make use of it in your
own practice?PRACTICE GUIDELINE SERIES
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• Dacarbazine and temozolomide may both be con-
sidered reasonable therapeutic choices in patients.
There is no reason to choose one over the other
insofar as outcomes (overall survival, disease-free
survival) are concerned. Patient preference and
factors such as intravenous access, geographic
location, and access to treatment facilities should
be taken into consideration.
• As previously acknowledged in this document,
the amount of high-quality evidence on the roles
of  IFN and thalidomide in combination with
temozolomide is limited. To date, only one small
RCT has shown that the combination of tem-
ozolomide and IFN demonstrates a statistically sig-
nificant difference in response rate. Perhaps the
ongoing phase II trial (Southwest Oncology
Group S0508) comparing thalidomide and
temozolomide in stage IV malignant melanoma
will provide favourable results for this combina-
tion treatment. When larger confirmatory trials
become available, the guideline will be updated
and the recommendations revisited. The Mela-
noma DSG previously submitted this practice
guideline report to the Drug Quality and Thera-
peutics Committee/Cancer Care Ontario (DQTC/
CCO) in 2005 for funding consideration.
7. REPORT APPROVAL PANEL
7.1 Results
After the practitioner feedback survey had been ad-
dressed, the practice guideline report was circulated
to the PEBC Report Approval Panel for further review.
The Panel consists of two members, including an
oncologist with expertise in clinical and methodol-
ogy issues. The final report was reviewed and ap-
proved by the Panel in March 2006 on condition that
the Melanoma DSG address these concerns:
• The justification for recommending temozolo-
mide appears to be based on the fact that it meets
the “benchmark” set by dacarbazine.
• Given the existing phase III and phase II studies,
the inclusion of single-arm trials has the poten-
tial to bias discussion.
7.2 Modifications/Actions
In response, the Melanoma DSG
• acknowledged the view that dacarbazine is widely
regarded as the standard of care—albeit one with
extremely limited efficacy in this disease. Fur-
thermore, the DSG members agree that
temozolomide at least meets this standard and
may be particularly applicable in the circum-
stances outlined in the report. Given that the
“standard” leaves much to be desired, the DSG
recommends that untreated patients be strongly
considered for clinical trials. A statement on
dacarbazine has been added to the discussion.
• The Melanoma DSG retained the single-arm trials
because the limited evidence available made their
inclusion appear necessary. The DSG members
realize that the results of these studies must be
interpreted with caution because of their
methodologic limitations, and they plan to refrain
from including them in future documents.
8. PRACTICE GUIDELINE
This practice guideline reflects the integration of the
draft recommendations with feedback obtained dur-
ing the external review process. It has been approved
by the Melanoma DSG and the Report Approval Panel
of the PBEC.
8.1 Target Population
The recommendations in this practice guideline ap-
ply to adult patients with unresectable metastatic
malignant melanoma.
8.2 Recommendations
Based on a systematic review of the available evi-
dence, the Melanoma DSG concludes that it is reason-
able to use temozolomide at a dose of 200 mg/m2
orally for 5 days every 4 weeks as initial systemic
treatment for patients with unresectable metastatic
malignant melanoma.
In a large randomized phase III study, the addition
of moderate-dose IFN has produced a significantly higher
response rate than has single-agent temozolomide.
However, overall survival was not altered and grades 3
and 4 hematologic toxicities were higher with the com-
bined treatment. At the present time, the addition of
interferon-a to temozolomide is not recommended.
One randomized phase II study and six other
phase II studies showed encouraging response rates
when thalidomide was combined with temozolomide.
However, the doses and schedules of temozolomide
in those studies differed from the conventionally pre-
scribed doses and schedules. It is not clear whether
the improved response rates were attributable to the
small number of patients in the studies, the different
temozolomide doses and schedules, or the addition
of thalidomide. Further phase III studies are required
to confirm whether a benefit is associated with the
combination of temozolomide and thalidomide.
Therefore, at this time, it is not recommended that
thalidomide be combined with temozolomide.
8.3 Qualifying Statements
Dacarbazine is the only chemotherapy drug currently
approved for the treatment of patients with metastaticQUIRT et al.
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malignant melanoma. In large randomized trials, re-
sponse rates with dacarbazine ranged from 6% to
15%. Almost all responses were partial, with a me-
dian response duration of only 7–8 months. Given
these disappointing overall results, the consensus
among most physicians who are treating patients with
metastatic malignant melanoma is that recommend-
ing more convenient treatment or experimental treat-
ment to these patients is appropriate.
Because of oral dosing, temozolomide is a rea-
sonable choice, particularly for patients who would
have difficulty travelling to cancer centres for intra-
venous chemotherapy.
Temozolomide has demonstrated efficacy equal
to that of dacarbazine in a randomized phase III trial.
However, unlike dacarbazine, temozolomide is a con-
venient oral treatment that penetrates the blood–brain
barrier and that has shown activity against brain me-
tastases. Although surgery is the preferred treatment
modality for patients with solitary brain metastases
from melanoma, temozolomide is the preferred che-
motherapy for patients with brain metastases who
require systemic treatment.
9. PRACTICE GUIDELINE DATE
Completed March 2006. Practice guidelines devel-
oped by the PBEC are reviewed and updated regularly.
Please visit the PEBC’s Web site (www.cancercare.on.
ca/access_PEBC.htm) for the full guideline report and
subsequent updates.
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